Cara Therapeutics, Inc. (CARA)

0,7071 -0,0233 (-3,19%) Börsenschluss: 04:00PM EDT

Cara Therapeutics, Inc.

400 Atlantic Street
Suite 500
Stamford, CT 06901
United States
203 406 3700
https://www.caratherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 55

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christopher A. Posner	President, CEO & Director	1,15M	N/A	1970
Mr. Ryan D. Maynard	Chief Financial Officer	670,7k	N/A	1969
Dr. Derek T. Chalmers D.Sc., Ph.D.	Co-Founder & Senior Advisor	580,93k	N/A	1964
Dr. Iris Francesconi Ph.D.	Chief Strategy Officer & Head of Investor Relations	N/A	N/A	N/A
Mr. Scott M. Terrillion	Chief Compliance Officer, General Counsel & Corporate Secretary	689,63k	N/A	1963
Ms. Beth Weinberg R.Ph.	Senior Vice President of Regulatory Affairs & QA	N/A	N/A	N/A
Mr. Matthew Murphy	Manager of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Corporate Governance

Cara Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 4, Vorstand: 4, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.